Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb 4Q

Pharmaceutical sales were $4.5 billion in the quarter (+4%). U.S. pharmaceutical sales were up 13% to $2.8 billion, while international sales were down 9% to $1.7 billion, primarily due to an 8% unfavorable foreign exchange impact.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb

4Q Revenues: $5.2 billion (+4%)

4Q Earnings: $1.2 billion (loss of $89 million in 4Q08)

FY Revenues: $20.6 billion (+13%)

FY Earnings: $5.2 billion (+142%)

Comments: Pharmaceutical sales were $4.5 billion in the quarter (+4%). U.S. pharmaceutical sales were up 13% to $2.8 billion, while international sales were down 9% to $1.7 billion, primarily due to an 8% unfavorable foreign exchange impact. Plavix sales were $1.5 billion (+7%). Pravachol sales were down 70% to $27 million due to generic competition. Baraclude sales were $153 million (+55%). Erbitux sales dropped 2% to $182 million. Sprycel sales were up 54% to $86 million and Ixempra sales were $25 million (+67%). Sustiva Franchise revenue was $300 million (+15%). Abilify sales were $606 million (+31%) and Orencia sales were up 72% to $129 million. R&D expenses were $1.1 billion (+29%). Earnings in the quarter include a $582 million after-tax gain related the sale of BMS’ stake in ImClone Systems.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters